3 recruiting, 2 not yet recruiting. 2 Phase 2, 1 Early Phase 1, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Castration Sensitive Prostate Cancer: new trials by email Literature Review of Castration Sensitive Prostate Cancer trials Research Report on Castration Sensitive Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11 - Prostate Cancer, Castration Sensitive Prostate Cancer | Early Phase 1 | Not yet recruiting | University of Texas Southwestern Medical Center | 30 | 2026-10-01 | 2026-08-24 |
| A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses - Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | 170 | 2026-09-01 | 2026-10-07 |
| Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) Recurrence-directed therapy (RDT), ELIGARD 22.5mg - Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 162 | 2026-05-06 | 2026-10-13 |
| Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan - Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 80 | 2024-06-25 | 2026-10-20 |
| A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy Metformin, Turmeric - Castration Sensitive Prostate Cancer | Phase 1 | Recruiting | University of Arkansas | 34 | 2024-04-11 | 2026-10-15 |
Prostatic Neoplasms (2) · Neoplasm Metastasis (1)
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Androgen Antagonists (1) · Curcumin (1) · Magnetic Resonance Spectroscopy (1) · Metformin (1) · Specimen Handling (1) · gallium 68 PSMA-11 (1) · luprolide acetate gel depot (1)
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute (1) · OHSU Knight Cancer Institute (1) · Ontario Clinical Oncology Group (OCOG) (1) · University of Arkansas (1) · University of Texas Southwestern Medical Center (1)
United States (3) · Canada (1) · India (1)
Jim Wright, Dr. (1) · Nadine Mallak, MD (1) · Shi-Ming Tu, MD (1) · Theos Tsakiridis, Dr. (1)